Literature DB >> 25230818

Bruton tyrosine kinase (Btk) suppresses osteoblastic differentiation.

Shoichi Kaneshiro1, Kosuke Ebina, Kenrin Shi, Kiyoshi Yoshida, Dai Otsuki, Hideki Yoshikawa, Chikahisa Higuchi.   

Abstract

The Tec family of nonreceptor tyrosine kinases has been shown to play a key role in inflammation and bone destruction. Bruton tyrosine kinase (Btk) has been the most widely studied because of its critical role in B cells. Furthermore, recent evidence has demonstrated that blocking Btk signaling is effective in ameliorating lymphoma progression and experimental arthritis. The role of Btk in osteoblastic differentiation has not been well elucidated. In this study, we demonstrated the role of Btk in osteoblastic differentiation and investigated the effects of a Btk inhibitor on osteoblastic differentiation in mouse preosteoblastic MC3T3-E1 cells, primary calvarial osteoblasts, and bone marrow stromal ST2 cells. Btk expression was detected in all three cell lines. Btk inhibition stimulated mRNA expression of osteoblastic markers (alkaline phosphatase, osteocalcin, and osterix) and promoted mineralization of the extracellular matrix. In addition, Btk knockdown caused increased mRNA expression of osteoblastic markers. Furthermore, Btk inhibition suppressed the phosphorylation of mitogen-activated protein kinase (MAPK), nuclear factor kappa B (NFκB), and protein kinase Cα (PKCα). Our results indicate that Btk may regulate osteoblastic differentiation through the MAPK, NFκB, and PKCα signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25230818     DOI: 10.1007/s00774-014-0612-8

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  27 in total

1.  BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2.

Authors:  Mi-Hye Lee; Tae-Geon Kwon; Hyo-Sang Park; John M Wozney; Hyun-Mo Ryoo
Journal:  Biochem Biophys Res Commun       Date:  2003-09-26       Impact factor: 3.575

Review 2.  Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.

Authors:  Tadeusz Robak; Ewa Robak
Journal:  Expert Opin Investig Drugs       Date:  2012-05-22       Impact factor: 6.206

3.  Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice.

Authors:  M de Weers; R G Mensink; M E Kraakman; R K Schuurman; R W Hendriks
Journal:  Hum Mol Genet       Date:  1994-01       Impact factor: 6.150

4.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

5.  Spleen tyrosine kinase suppresses osteoblastic differentiation through MAPK and PKCα.

Authors:  Kiyoshi Yoshida; Chikahisa Higuchi; Akio Nakura; Hideki Yoshikawa
Journal:  Biochem Biophys Res Commun       Date:  2011-07-18       Impact factor: 3.575

6.  Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells.

Authors:  S Gallea; F Lallemand; A Atfi; G Rawadi; V Ramez; S Spinella-Jaegle; S Kawai; C Faucheu; L Huet; R Baron; S Roman-Roman
Journal:  Bone       Date:  2001-05       Impact factor: 4.398

7.  Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.

Authors:  Lichuan Liu; Julie Di Paolo; Jim Barbosa; Hong Rong; Karin Reif; Harvey Wong
Journal:  J Pharmacol Exp Ther       Date:  2011-04-26       Impact factor: 4.030

8.  The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation.

Authors:  Seoung Hoon Lee; Taesoo Kim; Daewon Jeong; Nacksung Kim; Yongwon Choi
Journal:  J Biol Chem       Date:  2008-02-14       Impact factor: 5.157

9.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.

Authors:  D Vetrie; I Vorechovský; P Sideras; J Holland; A Davies; F Flinter; L Hammarström; C Kinnon; R Levinsky; M Bobrow
Journal:  Nature       Date:  1993-01-21       Impact factor: 49.962

10.  Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.

Authors:  S Tsukada; D C Saffran; D J Rawlings; O Parolini; R C Allen; I Klisak; R S Sparkes; H Kubagawa; T Mohandas; S Quan
Journal:  Cell       Date:  1993-01-29       Impact factor: 41.582

View more
  3 in total

1.  Cell-Based Double-Screening Method to Identify a Reliable Candidate for Osteogenesis-Targeting Compounds.

Authors:  Sho Fukuyasu; Hiroki Kayashima; Akihito Moribayashi; Shu Matsuoka; Atsuhiro Nagasaki; Hiroko Okawa; Hirofumi Yatani; Makio Saeki; Hiroshi Egusa
Journal:  Biomedicines       Date:  2022-02-11

2.  Role of the Btk-PLCγ2 Signaling Pathway in the Bone Destruction of Apical Periodontitis.

Authors:  Lina Wang; Hong Zhang; Ming Dong; Meina Zuo; Shuo Liu; Ying Lu; Weidong Niu
Journal:  Mediators Inflamm       Date:  2019-07-25       Impact factor: 4.711

3.  Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease.

Authors:  Antonio Garcia-Gomez; Tianlu Li; Carlos de la Calle-Fabregat; Javier Rodríguez-Ubreva; Laura Ciudad; Francesc Català-Moll; Gerard Godoy-Tena; Montserrat Martín-Sánchez; Laura San-Segundo; Sandra Muntión; Xabier Morales; Carlos Ortiz-de-Solórzano; Julen Oyarzabal; Edurne San José-Enériz; Manel Esteller; Xabier Agirre; Felipe Prosper; Mercedes Garayoa; Esteban Ballestar
Journal:  Nat Commun       Date:  2021-01-18       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.